FR19C1033I2 - Derives phosphores servant d'inhibiteurs de kinase - Google Patents
Derives phosphores servant d'inhibiteurs de kinaseInfo
- Publication number
- FR19C1033I2 FR19C1033I2 FR19C1033C FR19C1033C FR19C1033I2 FR 19C1033 I2 FR19C1033 I2 FR 19C1033I2 FR 19C1033 C FR19C1033 C FR 19C1033C FR 19C1033 C FR19C1033 C FR 19C1033C FR 19C1033 I2 FR19C1033 I2 FR 19C1033I2
- Authority
- FR
- France
- Prior art keywords
- kinase inhibitors
- phosphorus derivatives
- phosphorus
- derivatives
- kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 150000003017 phosphorus Chemical class 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/6533—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
- C07F9/6521—Six-membered rings
- C07F9/65218—Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
- C07F9/6521—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
- C07F9/65685—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine oxide or thioxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
- C07F9/657172—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and one oxygen atom being part of a (thio)phosphinic acid ester: (X = O, S)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
- C07F9/65846—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12831708P | 2008-05-21 | 2008-05-21 | |
US13749008P | 2008-07-31 | 2008-07-31 | |
US18879608P | 2008-08-13 | 2008-08-13 | |
US19296408P | 2008-09-23 | 2008-09-23 | |
US19293808P | 2008-09-23 | 2008-09-23 | |
PCT/US2009/044918 WO2009143389A1 (en) | 2008-05-21 | 2009-05-21 | Phosphorous derivatives as kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
FR19C1033I1 FR19C1033I1 (hr) | 2019-06-21 |
FR19C1033I2 true FR19C1033I2 (fr) | 2020-01-31 |
Family
ID=41340562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR19C1033C Active FR19C1033I2 (fr) | 2008-05-21 | 2019-05-17 | Derives phosphores servant d'inhibiteurs de kinase |
Country Status (26)
Country | Link |
---|---|
US (5) | US9012462B2 (hr) |
EP (2) | EP2300013B1 (hr) |
JP (7) | JP2011523646A (hr) |
KR (3) | KR101860057B1 (hr) |
CN (1) | CN102105150B (hr) |
AU (1) | AU2009248923B2 (hr) |
BR (1) | BRPI0908637B8 (hr) |
CA (1) | CA2723961C (hr) |
CY (2) | CY1119534T1 (hr) |
DK (1) | DK2300013T3 (hr) |
EA (1) | EA029131B1 (hr) |
ES (1) | ES2645689T3 (hr) |
FR (1) | FR19C1033I2 (hr) |
HK (1) | HK1158497A1 (hr) |
HR (1) | HRP20171534T8 (hr) |
HU (2) | HUE035029T2 (hr) |
IL (2) | IL208716B (hr) |
LT (2) | LT2300013T (hr) |
LU (1) | LUC00120I2 (hr) |
MX (2) | MX353308B (hr) |
NL (1) | NL300990I2 (hr) |
NO (2) | NO2300013T3 (hr) |
PL (1) | PL2300013T3 (hr) |
PT (1) | PT2300013T (hr) |
SI (1) | SI2300013T1 (hr) |
WO (1) | WO2009143389A1 (hr) |
Families Citing this family (167)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二(芳胺基)芳基化合物 |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
HUE035029T2 (en) * | 2008-05-21 | 2018-03-28 | Ariad Pharma Inc | Kinase inhibitor phosphorus derivatives |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
EP3549934A1 (en) | 2008-06-27 | 2019-10-09 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
WO2010056311A1 (en) | 2008-11-12 | 2010-05-20 | Ariad Pharmaceuticals, Inc. | Pyrazinopyrazines and derivatives as kinase inhibitors |
JP2012511575A (ja) | 2008-12-12 | 2012-05-24 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのアザインドール誘導体 |
KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Egfr 억제제 및 질환 치료방법 |
MX2011011875A (es) | 2009-05-08 | 2011-12-08 | Astellas Pharma Inc | Compuesto de carboxamida heterociclica diamino. |
TW201100441A (en) * | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
MA34299B1 (fr) | 2010-06-04 | 2013-06-01 | Hoffmann La Roche | Dérivés d'aminopyrimidine au titre de modulateurs de lrrk2 |
BR112013003388A2 (pt) | 2010-08-10 | 2016-07-12 | Celgene Avilomics Res Inc | sal de besilato de um inibidor de btk |
WO2012051587A1 (en) * | 2010-10-14 | 2012-04-19 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in egfr-driven cancers |
JP5957460B2 (ja) | 2010-11-01 | 2016-07-27 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | 複素環式化合物またはその使用 |
WO2012061303A1 (en) | 2010-11-01 | 2012-05-10 | Avila Therapeutics, Inc. | Heteroaryl compounds and uses thereof |
US8796255B2 (en) | 2010-11-10 | 2014-08-05 | Celgene Avilomics Research, Inc | Mutant-selective EGFR inhibitors and uses thereof |
AU2011328139A1 (en) | 2010-11-10 | 2013-04-04 | F. Hoffmann-La Roche Ag | Pyrazole aminopyrimidine derivatives as LRRK2 modulators |
US9133224B2 (en) | 2010-11-29 | 2015-09-15 | OSI Pharmaceuticals, LLC | Macrocyclic kinase inhibitors |
JP5916752B2 (ja) * | 2010-12-17 | 2016-05-11 | ノバルティス アーゲー | 5−クロロ−n2−(2−イソプロポキシ−5−メチル−4−ピペリジン−4−イル−フェニル)−n4[2−(プロパン−2−スルホニル)−フェニル]−ピリミジン−2,4−ジアミンの結晶形 |
ES2691673T3 (es) | 2011-02-17 | 2018-11-28 | Cancer Therapeutics Crc Pty Limited | Inhibidores de Fak |
DK2675794T3 (da) | 2011-02-17 | 2019-05-06 | Cancer Therapeutics Crc Pty Ltd | Selektive fak-inhibitorer |
EP2678021A4 (en) * | 2011-02-24 | 2015-07-01 | Jiangsu Hansoh Pharmaceutical | PHOSPHORUS COMPOUNDS AS A PROTEIN KINASE INHIBITOR |
MX351754B (es) | 2011-04-22 | 2017-10-27 | Signal Pharm Llc | Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y metodos de tratamiento con las mismas. |
EA201391626A1 (ru) * | 2011-05-04 | 2014-03-31 | Ариад Фармасьютикалз, Инк. | Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака |
WO2012166983A1 (en) * | 2011-05-31 | 2012-12-06 | Newgen Therapeutics, Inc. | Tricyclic inhibitors of poly(adp-ribose)polymerase |
WO2013013188A1 (en) | 2011-07-21 | 2013-01-24 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
AR088570A1 (es) | 2011-10-28 | 2014-06-18 | Celgene Avilomics Res Inc | Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton |
US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
US9586965B2 (en) | 2012-01-13 | 2017-03-07 | Acea Biosciences Inc. | Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases |
US9464089B2 (en) | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
EP2802568A1 (en) | 2012-01-13 | 2014-11-19 | Acea Biosciences, Inc. | Heterocyclic compounds and uses as anticancer agents. |
CN104284584B (zh) | 2012-03-15 | 2019-06-04 | 西建卡尔有限责任公司 | 表皮生长因子受体激酶抑制剂的盐 |
WO2013138495A1 (en) | 2012-03-15 | 2013-09-19 | Celgene Avilomics Research, Inc. | Solid forms of an epidermal growth factor receptor kinase inhibitor |
US20150166591A1 (en) * | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
CN103420902A (zh) * | 2012-05-18 | 2013-12-04 | 苏州爱斯鹏药物研发有限责任公司 | 一种2-氯-4-碘-5-甲基吡啶的制备方法 |
JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
RU2509770C2 (ru) * | 2012-06-22 | 2014-03-20 | Общество с ограниченной ответственностью "Молекулярные Технологии" | Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных |
KR101446742B1 (ko) | 2012-08-10 | 2014-10-01 | 한국화학연구원 | N2,n4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
KR102156398B1 (ko) * | 2012-11-06 | 2020-09-15 | 상하이 포천 파마슈티컬 씨오 엘티디 | Alk 키나아제 억제제 |
US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US9145387B2 (en) | 2013-02-08 | 2015-09-29 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
TW201522337A (zh) | 2013-03-12 | 2015-06-16 | Arqule Inc | 經取代之三環吡唑並-嘧啶化合物類 |
WO2014151871A2 (en) * | 2013-03-14 | 2014-09-25 | Tolero Pharmaceuticals, Inc. | Jak2 and alk2 inhibitors and methods for their use |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
CN103242341B (zh) * | 2013-04-19 | 2015-12-09 | 中国科学院广州生物医药与健康研究院 | 噻吩并2,4取代嘧啶类化合物及其药物组合物与应用 |
CN104470921B (zh) * | 2013-05-17 | 2017-05-03 | 上海恒瑞医药有限公司 | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
NZ715687A (en) | 2013-07-11 | 2019-04-26 | Acea Biosciences Inc | Pyrimidine derivatives as kinase inhibitors |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
ES2738573T3 (es) | 2013-10-16 | 2020-01-23 | Fujifilm Corp | Sal de compuesto heterocíclico que contiene nitrógeno o cristal del mismo, composición farmacéutica e inhibidor de FLT3 |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
NZ715903A (en) | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
KR101656382B1 (ko) | 2014-02-28 | 2016-09-09 | 한국화학연구원 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
AU2015266453C1 (en) * | 2014-05-30 | 2018-09-13 | Shanghai Emerald Wellcares Pharmaceutical Co., Ltd | Alk kinase inhibitor, and preparation method and use thereof |
CN106459007B (zh) | 2014-06-17 | 2020-02-28 | 韩国化学研究院 | 嘧啶-2,4-二胺衍生物及包含其作为有效成分的抗癌用药学组合物 |
US20160002248A1 (en) * | 2014-07-03 | 2016-01-07 | Board Of Regents, The University Of Texas System | Gls1 inhibitors for treating disease |
PT3164394T (pt) | 2014-07-03 | 2020-05-08 | Univ Texas | Inibidores gls1 para o tratamento de doenças |
ES2714576T3 (es) | 2014-07-04 | 2019-05-29 | Qilu Pharmaceutical Co Ltd | Oxido de arilfósforo y sulfuro de arilfósforo espirocíclicos |
CN105330698B (zh) * | 2014-07-04 | 2019-05-28 | 齐鲁制药有限公司 | 螺环芳基磷氧化物和硫化物 |
CN106459111B (zh) * | 2014-08-07 | 2019-05-31 | 江苏豪森药业集团有限公司 | 一种抗癌化合物的晶型及其制备方法和用途 |
CN106661064B (zh) * | 2014-08-07 | 2019-10-15 | 江苏豪森药业集团有限公司 | 一种抗癌化合物的新晶型及其制备方法和用途 |
CN105330697B (zh) * | 2014-08-07 | 2019-05-28 | 江苏豪森药业集团有限公司 | 一种抗癌化合物的晶型及其制备方法和用途 |
EP3179858B1 (en) | 2014-08-13 | 2019-05-15 | Celgene Car Llc | Forms and compositions of an erk inhibitor |
BR112017003186A2 (pt) | 2014-08-22 | 2017-11-28 | Fujifilm Corp | composição farmacêutica para tratamento de cancer positivo para mutação em flt3, inibidor de flt3 mutante e usos dos mesmos |
KR101633722B1 (ko) | 2014-10-08 | 2016-06-28 | 한국화학연구원 | 4-(1-퍼롤-3,4-디카르복시아미드)피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
HUE051693T2 (hu) * | 2014-10-21 | 2021-03-29 | Ariad Pharma Inc | 5-Klór-N4-[2-(dimetilfoszforil)-fenil]-N2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)-piperidin-1-il] -pirimidin-2,4-diamin kristályos formái |
US9796685B2 (en) | 2014-12-16 | 2017-10-24 | Signal Pharmaceuticals, Llc | Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-Methylcyclohexylamino)-pyrimidine-5-carboxamide |
WO2016100308A1 (en) | 2014-12-16 | 2016-06-23 | Signal Pharmaceuticals, Llc | Methods for measurement of inhibition of c-jun n-terminal kinase in skin |
CA2975260C (en) | 2015-01-29 | 2024-05-21 | Signal Pharmaceuticals Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
CN105985317B (zh) * | 2015-02-12 | 2018-09-18 | 正大天晴药业集团股份有限公司 | 一种色瑞替尼的制备方法及其中间体 |
KR101772134B1 (ko) | 2015-04-14 | 2017-08-29 | 한국화학연구원 | N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
CN106146468B (zh) * | 2015-04-17 | 2020-12-01 | 杭州雷索药业有限公司 | 吡啶酮类蛋白激酶抑制剂 |
KR101653571B1 (ko) | 2015-04-22 | 2016-09-05 | 한국화학연구원 | 4-(2-아미노-테트라하이드로나프탈렌닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
CN106188060A (zh) * | 2015-04-29 | 2016-12-07 | 厦门大学 | 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用 |
US20210323976A1 (en) * | 2015-05-13 | 2021-10-21 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
CN104892526A (zh) * | 2015-06-17 | 2015-09-09 | 药源药物化学(上海)有限公司 | 一种2,5-二氯-n-(2-(异丙基磺酰基)苯基)嘧啶-4-胺的制备方法 |
WO2017004359A1 (en) | 2015-06-30 | 2017-01-05 | Board Of Regents, University Of Texas System | Gls1 inhibitors for treating disease |
CN106336398A (zh) * | 2015-07-06 | 2017-01-18 | 杭州雷索药业有限公司 | 2‑饱和环基取代的苯胺类蛋白激酶抑制剂 |
WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
JP6412471B2 (ja) | 2015-07-15 | 2018-10-24 | 富士フイルム株式会社 | 含窒素複素環化合物の製造方法およびその中間体 |
AU2016297784B2 (en) | 2015-07-24 | 2020-12-24 | Celgene Corporation | Methods of synthesis of (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
CN105061506B (zh) * | 2015-07-27 | 2017-08-29 | 苏州明锐医药科技有限公司 | 抗肿瘤药物ap26113的制备方法 |
CN106478700B (zh) * | 2015-08-26 | 2020-12-29 | 杭州雷索药业有限公司 | 硼基取代的苯胺类蛋白激酶抑制剂 |
WO2017059702A1 (en) | 2015-10-09 | 2017-04-13 | Acea Biosciences, Inc | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same |
CN106699810A (zh) * | 2015-11-17 | 2017-05-24 | 清华大学 | 一种含氮杂环化合物及其制备方法与在抑制激酶活性中的应用 |
RU2606951C1 (ru) * | 2015-11-19 | 2017-01-10 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | Дихлорацетаты замещенных N4-[2-(диметилфосфорил)фенил]-N2-(2-метокси-4-пиперидин-1-илфенил)-5-хлорпиримидин-2,4-диаминов в качестве модуляторов ALK и EGFR, предназначенных для лечения рака |
JP6887430B2 (ja) * | 2015-11-27 | 2021-06-16 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. | 重水素化されたBrigatinib誘導体、かかる誘導体を含む薬学的組成物、並びにそれらの使用 |
CN108948082A (zh) * | 2015-12-02 | 2018-12-07 | 深圳市塔吉瑞生物医药有限公司 | 一种二氨基嘧啶化合物及包含该化合物的组合物 |
CN105294759B (zh) * | 2015-12-02 | 2018-01-19 | 苏州东南药业股份有限公司 | 一种抗肿瘤药物的制备方法 |
US10150753B2 (en) | 2015-12-22 | 2018-12-11 | Board Of Regents, The University Of Texas System | Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyrdin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide |
WO2017133663A1 (en) * | 2016-02-03 | 2017-08-10 | Shanghai Fochon Pharmaceutical Co., Ltd. | Phosphorus containing compounds as protein kinase inhibitors |
US10813933B2 (en) * | 2016-05-17 | 2020-10-27 | Japanese Foundation For Cancer Research | Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance |
CN106220608B (zh) | 2016-07-25 | 2018-11-27 | 安润医药科技(苏州)有限公司 | 二苯氨基嘧啶及三嗪化合物、其药用组合物及用途 |
CN107698603B (zh) | 2016-08-09 | 2022-04-08 | 南京红云生物科技有限公司 | 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用 |
WO2018075937A1 (en) * | 2016-10-21 | 2018-04-26 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
WO2018077187A1 (zh) * | 2016-10-25 | 2018-05-03 | 苏州晶云药物科技有限公司 | Ap26113的新晶型及其制备方法 |
JP7025426B2 (ja) * | 2016-11-30 | 2022-02-24 | アリアド ファーマシューティカルズ, インコーポレイテッド | 造血前駆体キナーゼ1(hpk1)阻害剤としてのアニリノピリミジンas |
WO2018108064A1 (zh) * | 2016-12-13 | 2018-06-21 | 南京明德新药研发股份有限公司 | 作为第四代egfr激酶抑制剂的螺环芳基磷氧化合物 |
MA48602A (fr) | 2016-12-13 | 2020-03-18 | Bristol Myers Squibb Co | Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha |
EP3592338A1 (en) | 2017-03-08 | 2020-01-15 | ARIAD Pharmaceuticals, Inc. | Pharmaceutical formulations comprising 5-chloro-n4 |
US11498922B2 (en) | 2017-04-07 | 2022-11-15 | ACEA Therapeutics, Inc. | Pharmaceutical composition comprising N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenylacrylamide |
JOP20190281A1 (ar) | 2017-06-13 | 2019-12-02 | Korea Res Inst Chemical Tech | مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه |
RU2020112558A (ru) | 2017-10-18 | 2021-11-18 | Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем | Терапия на основе ингибитора глутаминазы |
WO2019112344A1 (ko) | 2017-12-07 | 2019-06-13 | 주식회사 온코빅스 | 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물 |
KR101992621B1 (ko) | 2017-12-07 | 2019-09-27 | 주식회사 온코빅스 | 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물 |
KR102538307B1 (ko) * | 2017-12-13 | 2023-05-31 | 상하이테크 유니버시티 | Alk 단백질 분해제 및 암 치료에서의 이의 용도 |
CN109369721B (zh) * | 2017-12-21 | 2024-05-14 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制激酶活性的芳基磷氧化物 |
CN109627263B (zh) * | 2017-12-21 | 2022-05-20 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制激酶活性的二苯氨基嘧啶类化合物 |
EP3740206B1 (en) | 2018-01-16 | 2024-03-06 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2019143719A1 (en) | 2018-01-16 | 2019-07-25 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2019148789A1 (zh) * | 2018-02-02 | 2019-08-08 | 苏州科睿思制药有限公司 | 布格替尼的晶型及其制备方法 |
WO2019154091A1 (zh) * | 2018-02-07 | 2019-08-15 | 深圳市塔吉瑞生物医药有限公司 | 取代的二氨基嘧啶化合物 |
US20210046096A1 (en) | 2018-02-13 | 2021-02-18 | Sandoz Ag | Pharmaceutical Composition of Brigatinib |
US11529363B2 (en) | 2018-03-19 | 2022-12-20 | Takeda Pharmaceutical Company Limited | Methods of treating cancer in pediatric patients |
CN110305161A (zh) * | 2018-03-20 | 2019-10-08 | 暨南大学 | 2-氨基嘧啶类化合物及其应用 |
KR102548191B1 (ko) * | 2018-04-09 | 2023-06-28 | 상하이테크 유니버시티 | 표적 단백질 분해 화합물, 이의 항종양 응용, 이의 중간체 및 중간체의 응용 |
JP2021521170A (ja) | 2018-04-13 | 2021-08-26 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | 骨髄増殖性新生物およびがんに関連する線維症の処置のためのpimキナーゼ阻害剤 |
CN110467637B (zh) * | 2018-05-09 | 2022-02-18 | 北京赛特明强医药科技有限公司 | 一种含有氧化膦类取代苯胺的双氨基氯代嘧啶类化合物、制备方法及其应用 |
CN110467638A (zh) * | 2018-05-09 | 2019-11-19 | 北京赛特明强医药科技有限公司 | 一种含有间氯苯胺类取代基的双氨基氯代嘧啶类化合物、制备方法及其应用 |
CN110526941A (zh) * | 2018-05-24 | 2019-12-03 | 北京赛特明强医药科技有限公司 | 一种含有间氯苯胺类取代基的吡咯并嘧啶类化合物、制备方法及其应用 |
WO2019223777A1 (zh) * | 2018-05-24 | 2019-11-28 | 北京赛特明强医药科技有限公司 | 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用 |
KR20210038906A (ko) | 2018-07-26 | 2021-04-08 | 스미토모 다이니폰 파마 온콜로지, 인크. | 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제 |
CN109053693B (zh) * | 2018-09-20 | 2021-02-05 | 顺毅股份有限公司 | 哒嗪胺类化合物的制备及其应用 |
EA202191050A1 (ru) * | 2018-10-15 | 2022-03-17 | Общество С Ограниченной Ответственностью "Геро Дискавери" | Ингибиторы pfkfb3 и их использование |
WO2020088390A1 (zh) * | 2018-10-29 | 2020-05-07 | 江苏先声药业有限公司 | 作为第四代egfr抑制剂的嘧啶吡唑类化合物 |
US20210401859A1 (en) | 2018-11-01 | 2021-12-30 | Syros Pharmaceuticals, Inc. | Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2020099483A1 (en) | 2018-11-15 | 2020-05-22 | Sandoz Ag | Crystalline forms of brigatinib |
US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
EP3915985A4 (en) * | 2019-01-18 | 2022-09-28 | Voronoi Co., Ltd. | PYRROLOPYRIDINE DERIVATIVE AND ITS USE IN THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASE |
MX2021009371A (es) | 2019-02-12 | 2021-09-10 | Sumitomo Pharma Oncology Inc | Formulaciones que comprenden inhibidores de proteina cinasa heterociclicos. |
CN113939518A (zh) * | 2019-03-15 | 2022-01-14 | 杭州英创医药科技有限公司 | 作为激酶抑制剂的稠合三环化合物 |
EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
CN111825719A (zh) * | 2019-04-15 | 2020-10-27 | 北京赛特明强医药科技有限公司 | 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用 |
CN111848677B (zh) * | 2019-04-29 | 2023-03-17 | 浙江同源康医药股份有限公司 | 一种alk激酶抑制剂化合物的晶型、制备方法及应用 |
WO2020245208A1 (en) | 2019-06-04 | 2020-12-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
CN112047978A (zh) * | 2019-06-05 | 2020-12-08 | 北京赛思源生物医药技术有限公司 | 5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺新晶型 |
KR20220028075A (ko) | 2019-07-03 | 2022-03-08 | 스미토모 다이니폰 파마 온콜로지, 인크. | 티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도 |
WO2021073498A1 (zh) * | 2019-10-17 | 2021-04-22 | 贝达药业股份有限公司 | Egfr抑制剂、组合物及其制备方法 |
CN110713497A (zh) * | 2019-10-30 | 2020-01-21 | 成都海杰亚医药科技有限公司 | 一种Brigatinib的中间体2-氨基苯基二甲基氧化膦制备方法 |
KR102168179B1 (ko) | 2019-10-31 | 2020-10-20 | 주식회사 온코빅스 | 암세포 성장 억제 효과를 나타내는 신규한 헤테로 고리 치환 피리미딘 유도체 및 그를 포함하는 약제학적 조성물 |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
CN114728932A (zh) * | 2019-11-29 | 2022-07-08 | 江苏先声药业有限公司 | 作为egfr激酶抑制剂的多芳基化合物 |
WO2021125803A1 (ko) * | 2019-12-16 | 2021-06-24 | 한국화학연구원 | 신규한 피리미딘 유도체 및 이의 용도 |
KR20220113933A (ko) | 2019-12-16 | 2022-08-17 | 주식회사 온코빅스 | 신규한 중수소 치환 피리미딘 유도체 및 이를 포함하는 약제학적 조성물 |
BR112022011834A2 (pt) * | 2019-12-16 | 2022-08-30 | Korea Res Inst Chemical Tech | Derivado de pirimidina e uso do mesmo |
CN111138492B (zh) * | 2020-01-06 | 2022-08-02 | 沈阳药科大学 | Alk抑制剂布格替尼的制备方法 |
CN114787154A (zh) * | 2020-01-19 | 2022-07-22 | 苏州科睿思制药有限公司 | 一种Deucravacitinib的晶型及其制备方法和用途 |
CN111620852B (zh) * | 2020-01-19 | 2023-05-09 | 镇江植生源农业科技有限公司 | 一种5-氯-嘧啶-2,4-二胺类化合物及其制备方法和应用 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
TW202204339A (zh) | 2020-03-31 | 2022-02-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 經取代的嘧啶及使用方法 |
CA3184218A1 (en) * | 2020-07-03 | 2022-01-06 | Peng HE | Aryl phosphorus oxide compounds and use thereof |
CN112225703B (zh) * | 2020-09-28 | 2022-03-11 | 广州智睿医药科技有限公司 | 一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物 |
CA3208361A1 (en) | 2021-02-19 | 2022-08-25 | Anjali Pandey | Tyk2 inhibitors and uses thereof |
WO2022199589A1 (zh) * | 2021-03-23 | 2022-09-29 | 南京明德新药研发有限公司 | 嘧啶衍生物 |
EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
EP4330251A1 (en) * | 2021-04-30 | 2024-03-06 | BeiGene Switzerland GmbH | Egfr degraders and associated methods of use |
CN117412981A (zh) * | 2021-06-03 | 2024-01-16 | 希格生科(深圳)有限公司 | 氧化膦衍生物及其制备方法和应用 |
CN117500813A (zh) * | 2021-06-17 | 2024-02-02 | 微境生物医药科技(上海)有限公司 | 芳基氧膦类化合物 |
WO2023025164A1 (zh) * | 2021-08-27 | 2023-03-02 | 成都地奥九泓制药厂 | 芳基磷氧化合物的晶型、制备方法及用途 |
TW202333667A (zh) * | 2021-12-13 | 2023-09-01 | 大陸商希格生科(深圳)有限公司 | 嘧啶或吡啶類衍生物及其醫藥用途 |
WO2023204822A1 (en) * | 2022-04-22 | 2023-10-26 | Vivace Therapeutics, Inc. | Phenyl phosphine oxide compounds and methods of use thereof |
CN117045664A (zh) * | 2022-08-04 | 2023-11-14 | 中国人民解放军陆军特色医学中心 | 布格替尼作为st3gal4抑制剂的新应用 |
CN115448906B (zh) * | 2022-09-26 | 2024-04-02 | 深圳大学 | 一种2-苯胺基嘧啶类衍生物及其制备方法与应用 |
WO2024079252A1 (en) | 2022-10-13 | 2024-04-18 | Bayer Aktiengesellschaft | Sos1 inhibitors |
WO2024088400A1 (zh) * | 2022-10-27 | 2024-05-02 | 勤浩医药(苏州)有限公司 | 含磷化合物、药物组合物及其应用 |
WO2024097653A1 (en) | 2022-10-31 | 2024-05-10 | Sumitomo Pharma America, Inc. | Pim1 inhibitor for treating myeloproliferative neoplasms |
CN115785154A (zh) * | 2022-12-01 | 2023-03-14 | 希格生科(深圳)有限公司 | 杂芳环化合物及其医药用途 |
Family Cites Families (283)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1129797A (en) | 1966-03-31 | 1968-10-09 | Ici Ltd | Phosphorus-containing pyrimidine derivatives and biologically active compositions containing them |
US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
EP0391451A1 (en) | 1986-04-17 | 1990-10-10 | Imperial Chemical Industries Plc | Fungicides |
US4966622A (en) | 1988-04-12 | 1990-10-30 | Ciba-Geigy Corporation | N-phenyl-N-pyrimidin-2-ylureas |
GB8828222D0 (en) | 1988-12-02 | 1989-01-05 | Ici Plc | Reactive dyes |
GB8903019D0 (en) | 1989-02-10 | 1989-03-30 | Ici Plc | Fungicides |
US5175383A (en) | 1989-02-17 | 1992-12-29 | President And Fellows Of Harvard College | Animal model for benign prostatic disease |
GB9016584D0 (en) | 1990-07-27 | 1990-09-12 | Ici Plc | Fungicides |
DE69129611T2 (de) | 1990-08-20 | 1998-12-17 | Eisai Co Ltd | Sulfonamid-Derivate |
GB9220964D0 (en) | 1991-11-15 | 1992-11-18 | Ici Plc | Anionic compounds |
TW225528B (hr) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
JPH08503971A (ja) | 1993-10-01 | 1996-04-30 | チバ−ガイギー アクチェンゲゼルシャフト | ピリミジンアミン誘導体及びその調製のための方法 |
CA2174080A1 (en) | 1993-10-12 | 1995-04-20 | Paul Edward Aldrich | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
CA2214685C (en) | 1995-03-10 | 2008-05-20 | Berlex Laboratories, Inc. | Benzamidine derivatives their preparation and their use as anti-coagulants |
US5728201A (en) | 1995-09-14 | 1998-03-17 | Canon Kabushiki Kaisha | Ink, and ink-jet recording method and instruments using the same |
GB9519197D0 (en) | 1995-09-20 | 1995-11-22 | Affinity Chromatography Ltd | Novel affinity ligands and their use |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
WO1997020822A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Quinazolin-2,4-diazirines as npy receptor antagonist |
GB9608771D0 (en) | 1996-04-27 | 1996-07-03 | Agrevo Uk Ltd | Pyrimethanil salts |
JP3106966B2 (ja) | 1996-07-17 | 2000-11-06 | 富士ゼロックス株式会社 | インクジェット記録用インク及びインクジェット記録方法 |
JPH1060338A (ja) | 1996-08-21 | 1998-03-03 | Fuji Xerox Co Ltd | インクジェット記録用インク及びインクジェット記録方法 |
US6008234A (en) | 1996-09-12 | 1999-12-28 | Berlex Laboratories, Inc. | Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants |
CN1234798A (zh) | 1996-09-12 | 1999-11-10 | 舍林股份公司 | 环状氨基酸和环状羟基羧酸衍生物取代的苄脒衍生物和它们用作抗凝剂的用途 |
US6004985A (en) | 1996-10-09 | 1999-12-21 | Berlex Laboratories, Inc. | Thio acid derived monocylic N-heterocyclics as anticoagulants |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
US6573044B1 (en) | 1997-08-07 | 2003-06-03 | The Regents Of The University Of California | Methods of using chemical libraries to search for new kinase inhibitors |
JPH1160573A (ja) | 1997-08-22 | 1999-03-02 | Nippon Kayaku Co Ltd | トリアジン誘導体及びテロメラーゼ阻害剤 |
DE69839735D1 (de) | 1997-12-15 | 2008-08-28 | Astellas Pharma Inc | Pyrimidin-5-carboxamid-derivate |
DE59905472D1 (de) | 1998-06-10 | 2003-06-12 | Basf Ag | Verwendung von 2-(n-phenylamino)pyrimidinen als fungizide sowie neue 2-(n-phenylamino)pyrimidine |
AU5648599A (en) | 1998-09-11 | 2000-04-03 | Kyorin Pharmaceutical Co. Ltd. | Phosphonic ester derivatives and process for producing the same |
OA11674A (en) | 1998-11-10 | 2005-01-12 | Janssen Pharmaceutica Nv | HIV Replication inhibiting pyrimidines. |
NZ511311A (en) | 1998-11-17 | 2002-10-25 | Kumiai Chemical Industry Co | Pyrimidinylbenzimidazole and triazinylbenzimidazole derivatives useful as agricultural, horticultural bactericides |
US6262088B1 (en) | 1998-11-19 | 2001-07-17 | Berlex Laboratories, Inc. | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants |
US6127376A (en) | 1998-12-04 | 2000-10-03 | Berlex Laboratories, Inc. | Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants |
WO2000046203A2 (en) | 1999-02-04 | 2000-08-10 | Millennium Pharmaceuticals, Inc. | G-protein coupled heptahelical receptor binding compounds and methods of use thereof |
GB9910807D0 (en) | 1999-05-10 | 1999-07-07 | Prometic Biosciences Limited | Novel detoxification agents and their use |
GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9918035D0 (en) | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
ES2306671T3 (es) | 1999-10-07 | 2008-11-16 | Amgen Inc. | Inhibidores de triazina quinasa. |
ITMI992711A1 (it) | 1999-12-27 | 2001-06-27 | Novartis Ag | Composti organici |
CN1429222A (zh) * | 2000-02-17 | 2003-07-09 | 安姆根有限公司 | 激酶抑制剂 |
GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
US7087608B2 (en) | 2000-03-03 | 2006-08-08 | Robert Charles Atkins | Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
US6525051B2 (en) | 2000-03-27 | 2003-02-25 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
AU782948B2 (en) | 2000-05-08 | 2005-09-15 | Janssen Pharmaceutica N.V. | Prodrugs of HIV replication inhibiting pyrimidines |
EP1282606B1 (en) | 2000-05-08 | 2015-04-22 | Janssen Pharmaceutica NV | Hiv replication inhibiting pyrimidines and triazines |
US7238525B2 (en) | 2000-06-30 | 2007-07-03 | The Regents Of The University Of California | Strategy for leukemia therapy |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
GB0022438D0 (en) | 2000-09-13 | 2000-11-01 | Novartis Ag | Organic Compounds |
CA2422367C (en) | 2000-09-15 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
ATE302822T1 (de) | 2000-12-05 | 2005-09-15 | Clariant Finance Bvi Ltd | Trichromie-faerbeverfahren |
ES2324981T3 (es) | 2000-12-21 | 2009-08-21 | Smithkline Beecham Corporation | Pirimidinaminas como moduladores de la angiogenesis. |
US6881737B2 (en) | 2001-04-11 | 2005-04-19 | Amgen Inc. | Substituted triazinyl acrylamide derivatives and methods of use |
PT1399468E (pt) | 2001-05-30 | 2006-05-31 | Novartis Ag | Derivados do acido 2-{[n-(2-amino-3-(heteroaril ou aril)propionil)-aminoacil]-amino}-alquilboronico |
ATE432929T1 (de) | 2001-06-15 | 2009-06-15 | Vertex Pharma | 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer |
GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
US6878697B2 (en) * | 2001-06-21 | 2005-04-12 | Ariad Pharmaceuticals, Inc. | Phenylamino-pyrimidines and uses thereof |
AU2002350105A1 (en) | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
US20030186324A1 (en) | 2001-09-07 | 2003-10-02 | Irm Llc, A Delaware Limited Liability Company | Sensory neuron receptors |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
US20060009642A1 (en) | 2001-10-12 | 2006-01-12 | Irm Llc, A Delaware Limited Liability Company | Methods for the synthesis of substituted purines |
US6949644B2 (en) | 2001-10-12 | 2005-09-27 | Irm Llc | Methods for the synthesis of substituted purines |
AU2002342051B2 (en) | 2001-10-12 | 2009-06-11 | Irm Llc | Kinase inhibitor scaffolds and methods for their preparation |
US6770652B2 (en) * | 2001-10-18 | 2004-08-03 | Duquesne University Of The Holy Ghost | Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same |
CA2463822A1 (en) | 2001-11-01 | 2003-05-08 | Janssen Pharmaceutica N.V. | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) |
AU2003206397B2 (en) | 2002-01-04 | 2008-07-17 | The Rockefeller University | Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders |
EP2407473A3 (en) | 2002-02-01 | 2012-03-21 | ARIAD Pharmaceuticals, Inc | Method for producing phosphorus-containing compounds |
MXPA04007637A (es) | 2002-02-08 | 2004-11-10 | Smithkline Beecham Corp | Compuestos de pirimidina. |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
US7462608B2 (en) * | 2002-04-26 | 2008-12-09 | Gilead Sciences, Inc. | Non nucleoside reverse transcriptase inhibitors |
US20050239054A1 (en) | 2002-04-26 | 2005-10-27 | Arimilli Murty N | Method and compositions for identifying anti-HIV therapeutic compounds |
US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
AU2003231231A1 (en) | 2002-05-06 | 2003-11-11 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
AR039540A1 (es) | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
CA2486853A1 (en) | 2002-05-27 | 2003-12-04 | Novartis Ag | Bis-aromatic alkanols |
GB0217431D0 (en) | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
MXPA05001096A (es) | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
DE60318219T2 (de) | 2002-08-24 | 2009-01-15 | Astrazeneca Ab | PYRIMIDINDERIVATE ALS MODULATOREN DER AKTIVITuT VON CHEMOKINREZEPTOREN |
AU2003286876A1 (en) | 2002-11-01 | 2004-06-07 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of jak and other protein kinases |
AU2004213173B2 (en) | 2003-02-07 | 2010-07-29 | Janssen Pharmaceutica N.V. | HIV inhibiting 1,2,4-triazines |
EP1594508B1 (en) | 2003-02-11 | 2012-08-08 | Irm Llc | Novel bicyclic compounds and compositions |
ES2325440T3 (es) | 2003-02-20 | 2009-09-04 | Smithkline Beecham Corporation | Compuestos de pirimidina. |
CL2004000303A1 (es) | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
WO2004078682A2 (en) | 2003-03-05 | 2004-09-16 | Irm Llc | Cyclic compounds and compositions as protein kinase inhibitors |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
US7253166B2 (en) | 2003-04-22 | 2007-08-07 | Irm Llc | 6-phenyl-7H-pyrrolo[2,3-d]pyrimidine compounds that induce neuronal differentiation in embryonic stem cells |
WO2004098520A2 (en) | 2003-05-01 | 2004-11-18 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
US7317027B2 (en) | 2003-05-19 | 2008-01-08 | Sanofi-Aventis Deutschland Gmbh | Azaindole-derivatives as factor Xa inhibitors |
BRPI0413005A (pt) | 2003-07-29 | 2006-09-26 | Irm Llc | compostos e composições como inibidores da proteìna cinase |
KR20120062863A (ko) | 2003-07-30 | 2012-06-14 | 리겔 파마슈티칼스, 인크. | 자가면역 질환의 치료 또는 예방에 사용하기 위한 2,4-피리미딘디아민 화합물 |
DE602004032446D1 (de) | 2003-08-07 | 2011-06-09 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
CA2535620A1 (en) | 2003-08-15 | 2005-02-24 | Irm Llc | 6-substituted anilino purines as rtk inhibitors |
CA2533320A1 (en) * | 2003-08-15 | 2006-02-24 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
US7338957B2 (en) | 2003-08-28 | 2008-03-04 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
GB0321710D0 (en) | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
EP1663992A1 (en) | 2003-09-18 | 2006-06-07 | Novartis AG | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
JP2007507531A (ja) | 2003-09-30 | 2007-03-29 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
CA2540518A1 (en) | 2003-10-02 | 2005-04-07 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
AU2004279427B2 (en) | 2003-10-08 | 2008-07-03 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
DE10349587A1 (de) | 2003-10-24 | 2005-05-25 | Merck Patent Gmbh | Benzimidazolylderivate |
US7273715B2 (en) | 2003-10-24 | 2007-09-25 | Gilead Sciences, Inc. | Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase A |
WO2005047280A1 (en) | 2003-11-10 | 2005-05-26 | Merck Sharp & Dohme Limited | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain |
WO2005059668A1 (de) | 2003-12-01 | 2005-06-30 | Tuchenhagen Gmbh | Verfahren und anordnung zur zeitnahen überwachung, erfassung und übermittlung von prozessdaten |
PT1689715E (pt) | 2003-12-03 | 2011-05-16 | Ym Biosciences Australia Pty | Inibidores da tubulina |
MY141255A (en) | 2003-12-11 | 2010-03-31 | Memory Pharm Corp | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs |
US7511137B2 (en) | 2003-12-19 | 2009-03-31 | Rigel Pharmaceuticals, Inc. | Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates |
WO2005072530A1 (en) | 2004-01-16 | 2005-08-11 | Merck & Co., Inc. | Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor |
AU2005206541A1 (en) | 2004-01-16 | 2005-08-04 | Wyeth | Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof |
PL1713806T3 (pl) | 2004-02-14 | 2013-09-30 | Irm Llc | Związki i kompozycje jako inhibitory kinaz białkowych |
CA2566707A1 (en) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
JP4812763B2 (ja) | 2004-05-18 | 2011-11-09 | ライジェル ファーマシューティカルズ, インコーポレイテッド | シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途 |
EP1598343A1 (de) | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
EP1758892B1 (en) | 2004-06-10 | 2012-10-17 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
JP2008504281A (ja) | 2004-06-23 | 2008-02-14 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
US7923554B2 (en) | 2004-08-10 | 2011-04-12 | Janssen Pharmaceutica N.V. | HIV inhibiting 1,2,4-triazin-6-one derivatives |
US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
GB0419161D0 (en) | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | N型カルシウムチャネル阻害薬 |
EP1799652A1 (en) | 2004-10-13 | 2007-06-27 | Wyeth | N-benzenesulfonyl substituted anilino-pyrimidine analogs |
GT200500321A (es) | 2004-11-09 | 2006-09-04 | Compuestos y composiciones como inhibidores de proteina kinase. | |
GB2420559B (en) | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
JP5132319B2 (ja) | 2004-12-21 | 2013-01-30 | スミスクライン ビーチャム コーポレーション | 2−ピリミジニルピラゾロピリジンErbBキナーゼ阻害剤 |
WO2006074057A2 (en) | 2004-12-30 | 2006-07-13 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
EP2161275A1 (en) * | 2005-01-19 | 2010-03-10 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
BRPI0607307A2 (pt) | 2005-01-26 | 2009-08-25 | Irm Llc | compostos e composições como inibidores de proteìna cinase |
TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
CN101500574A (zh) | 2005-03-15 | 2009-08-05 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
EP1863794A2 (en) | 2005-03-16 | 2007-12-12 | Targegen, Inc. | Pyrimidine compounds and methods of use |
DE102005016634A1 (de) | 2005-04-12 | 2006-10-19 | Merck Patent Gmbh | Neuartige Aza-Hetercyclen als Kinase-Inhibitoren |
WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
ATE492545T1 (de) | 2005-05-13 | 2011-01-15 | Irm Llc | Verbindungen und zusammensetzungen als proteinkinase-hemmer |
CA2608333A1 (en) | 2005-05-16 | 2006-11-23 | Irm Llc | Pyrrolopyridine derivatives as protein kinase inhibitors |
WO2006123165A2 (en) | 2005-05-19 | 2006-11-23 | Astex Therapeutics Limited | Pyrimidine derivatives as hsp90 inhibitors |
WO2006128172A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating b cell regulated autoimmune disorders |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
WO2006129100A1 (en) | 2005-06-03 | 2006-12-07 | Glaxo Group Limited | Novel compounds |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
WO2007005673A1 (en) | 2005-07-01 | 2007-01-11 | Irm Llc | Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors |
US20070032514A1 (en) | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
AU2006268531A1 (en) | 2005-07-11 | 2007-01-18 | Sanofi-Aventis | Novel 2,4-dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as IKK inhibitors |
KR20080034483A (ko) | 2005-07-26 | 2008-04-21 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제의 억제제로서 유용한 벤즈이미다졸 |
CN101273023A (zh) | 2005-08-02 | 2008-09-24 | Irm责任有限公司 | 作为蛋白激酶抑制剂的5-取代的噻唑-2-基氨基化合物和组合物 |
JP2009504665A (ja) | 2005-08-09 | 2009-02-05 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
US8071609B2 (en) | 2005-08-11 | 2011-12-06 | Ariad Pharmaceuticals, Inc. | Unsaturated heterocyclic derivatives |
EP1919924A2 (en) | 2005-08-16 | 2008-05-14 | Irm, Llc | Compounds and compositions as protein kinase inhibitors |
US7973060B2 (en) | 2005-10-13 | 2011-07-05 | Crystalgenomics, Inc. | Fab I inhibitor and process for preparing same |
PE20070593A1 (es) | 2005-10-13 | 2007-07-23 | Glaxo Group Ltd | Compuestos pirrolopirimidina como inhibidores de syk |
WO2007048065A2 (en) | 2005-10-21 | 2007-04-26 | Exelixis, Inc. | Pyrimidinones as casein kinase ii (ck2) modulators |
ES2332423T3 (es) | 2005-10-28 | 2010-02-04 | Irm Llc | Compuestos y composiciones como inhibidores de proteina quinasas. |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
EP1943233A2 (en) | 2005-11-03 | 2008-07-16 | Irm, Llc | Compounds and compositions for protein kinase inhbitors |
CN101326182B (zh) | 2005-12-05 | 2011-09-28 | 史密丝克莱恩比彻姆公司 | 2-嘧啶基吡唑并吡啶ErbB激酶抑制剂 |
WO2007120339A1 (en) | 2005-12-19 | 2007-10-25 | Genentech, Inc. | Pyrimidine kinase inhibitors |
DE102005062742A1 (de) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
TW200736232A (en) | 2006-01-26 | 2007-10-01 | Astrazeneca Ab | Pyrimidine derivatives |
WO2007089768A2 (en) | 2006-01-30 | 2007-08-09 | Exelixis, Inc. | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them |
CA2637225A1 (en) | 2006-02-06 | 2007-08-16 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
TW200804364A (en) | 2006-02-22 | 2008-01-16 | Boehringer Ingelheim Int | New compounds |
US20070208164A1 (en) | 2006-02-27 | 2007-09-06 | Wyeth | Methods of synthesizing radiolabeled 3-cyano[14C]quinolines |
ES2465666T3 (es) | 2006-03-30 | 2014-06-06 | Janssen R&D Ireland | Pirimidinas 5-amido-sustituidas inhibidoras del HIV |
WO2007113256A1 (en) | 2006-03-30 | 2007-10-11 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines |
GB0608386D0 (en) | 2006-04-27 | 2006-06-07 | Senexis Ltd | Compounds |
US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
WO2007136465A2 (en) | 2006-05-15 | 2007-11-29 | Irm Llc | Compositions and methods for fgf receptor kinases inhibitors |
DE102006027156A1 (de) | 2006-06-08 | 2007-12-13 | Bayer Schering Pharma Ag | Sulfimide als Proteinkinaseinhibitoren |
WO2008005538A2 (en) | 2006-07-05 | 2008-01-10 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
GB0614579D0 (en) | 2006-07-21 | 2006-08-30 | Black James Foundation | Pyrimidine derivatives |
BRPI0715418A2 (pt) | 2006-07-21 | 2013-03-26 | Novartis Ag | compostos de 2,4-di(arilaminio)-pirimidina-5-carboxamida como inibidores de cinases jak |
DE102006041382A1 (de) | 2006-08-29 | 2008-03-20 | Bayer Schering Pharma Ag | Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren |
WO2008039359A2 (en) | 2006-09-25 | 2008-04-03 | Janssen Pharmaceutica N.V. | Bicyclic pyrimidine kinase inhibitors |
WO2008045978A1 (en) | 2006-10-10 | 2008-04-17 | Rigel Pharmaceuticals, Inc. | Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors |
CA2598893C (en) | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
ES2381215T3 (es) | 2006-10-19 | 2012-05-24 | Signal Pharmaceuticals Llc | Compuestos heteroarilo, sus composiciones y métodos de tratamiento con ellos |
CA2673125C (en) | 2006-10-19 | 2015-04-21 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
EP2222647B1 (en) | 2006-10-23 | 2015-08-05 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
WO2008057280A1 (en) | 2006-10-27 | 2008-05-15 | Amgen Inc. | Multi-cyclic compounds and methods of use |
US7982033B2 (en) | 2006-11-03 | 2011-07-19 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
BRPI0720264B1 (pt) | 2006-12-08 | 2022-03-03 | Novartis Ag | Compostos e composições como inibidores de proteína cinase |
EP2537830A1 (en) | 2006-12-08 | 2012-12-26 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
CN101563327A (zh) | 2006-12-19 | 2009-10-21 | 健泰科生物技术公司 | 嘧啶类激酶抑制剂 |
EP1939185A1 (de) | 2006-12-20 | 2008-07-02 | Bayer Schering Pharma Aktiengesellschaft | Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs |
WO2008081928A1 (ja) | 2006-12-28 | 2008-07-10 | Taisho Pharmaceutical Co., Ltd. | ピラゾロピリミジン化合物 |
EP2114901B1 (en) | 2006-12-29 | 2014-04-09 | Janssen R&D Ireland | Hiv inhibiting 6-substituted pyrimidines |
EP2114902B1 (en) | 2006-12-29 | 2014-09-17 | Janssen R&D Ireland | Hiv inhibiting 5,6-substituted pyrimidines |
FR2911138B1 (fr) | 2007-01-05 | 2009-02-20 | Sanofi Aventis Sa | Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
EP2124954A2 (en) * | 2007-01-26 | 2009-12-02 | Irm Llc | Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases |
TW200902010A (en) | 2007-01-26 | 2009-01-16 | Smithkline Beecham Corp | Anthranilamide inhibitors of aurora kinase |
AU2008210266B2 (en) | 2007-01-31 | 2013-09-05 | Ym Biosciences Australia Pty Ltd | Thiopyrimidine-based compounds and uses thereof |
TW200834459A (en) | 2007-02-05 | 2008-08-16 | Huper Lab Co Ltd | Video object segmentation method applied for rainy situations |
DE102007010801A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Cropscience Ag | Diaminopyrimidine als Fungizide |
CA2681248A1 (en) | 2007-03-20 | 2008-09-25 | Smithkline Beecham Corporation | Chemical compounds |
KR20090121399A (ko) | 2007-03-20 | 2009-11-25 | 스미스클라인 비참 코포레이션 | 화합물 |
WO2008118822A1 (en) | 2007-03-23 | 2008-10-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
NZ579892A (en) | 2007-03-30 | 2012-03-30 | Sanofi Aventis | Pyrimidine hydrazide compounds as prostaglandin D synthase inhibitors |
TWI433677B (zh) | 2007-06-04 | 2014-04-11 | Avila Therapeutics Inc | 雜環化合物及其用途 |
US20110053932A1 (en) | 2007-06-21 | 2011-03-03 | Irm Llc | Protein Kinase Inhibitors and Methods for Using Thereof |
TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二(芳胺基)芳基化合物 |
CN101903357A (zh) | 2007-07-17 | 2010-12-01 | 里格尔药品股份有限公司 | 作为pkc抑制剂的环状胺取代的嘧啶二胺 |
US7981903B2 (en) | 2007-08-08 | 2011-07-19 | Glaxosmithkline Llc | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer |
WO2009032703A1 (en) | 2007-08-28 | 2009-03-12 | Irm Llc | 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors |
BRPI0815979A2 (pt) | 2007-08-28 | 2017-06-13 | Irm Llc | compostos e composições com inibidores de quinase, bem como uso dos mesmos |
US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
AU2008314632B2 (en) | 2007-10-19 | 2015-05-28 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
CN104311563B (zh) | 2007-11-28 | 2016-12-07 | 达那-法伯癌症研究所 | Bcr-abl的小分子豆蔻酸酯抑制剂及其使用方法 |
EP2231620A1 (en) | 2007-12-03 | 2010-09-29 | Boehringer Ingelheim International GmbH | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
EP2234986A2 (en) | 2007-12-20 | 2010-10-06 | Cellzome Limited | Sulfamides as zap-70 inhibitors |
US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
MX2010006736A (es) | 2007-12-21 | 2010-10-15 | Avila Therapeutics Inc | Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos. |
MX2010006738A (es) | 2007-12-21 | 2010-10-15 | Avila Therapeutics Inc | Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos. |
US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
EP2229217A1 (en) | 2008-01-14 | 2010-09-22 | Irm Llc | Compositions and methods for treating cancers |
JP2011511949A (ja) | 2008-02-12 | 2011-04-14 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | 肺癌におけるeml4とalkの融合のためのfishアッセイ |
WO2009109605A1 (en) | 2008-03-05 | 2009-09-11 | Novartis Ag | Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members |
US20110098288A1 (en) | 2008-03-11 | 2011-04-28 | Jeremy Major | Sulfonamides as zap-70 inhibitors |
CL2009000600A1 (es) | 2008-03-20 | 2010-05-07 | Bayer Cropscience Ag | Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas. |
JP5214799B2 (ja) | 2008-04-07 | 2013-06-19 | アイアールエム・リミテッド・ライアビリティ・カンパニー | キナーゼ阻害剤としての化合物および組成物 |
WO2009126515A1 (en) | 2008-04-07 | 2009-10-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
WO2009127642A2 (en) | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
US20110071197A1 (en) | 2008-04-16 | 2011-03-24 | Peter Nilsson | Bis-aryl compounds for use as medicaments |
CN103224497A (zh) | 2008-04-22 | 2013-07-31 | 波托拉医药品公司 | 蛋白激酶抑制剂 |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US20130225527A1 (en) | 2008-05-21 | 2013-08-29 | Ariad Pharmaceuticals, Inc. | Phosphorus Derivatives as Kinase Inhibitors |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
HUE035029T2 (en) * | 2008-05-21 | 2018-03-28 | Ariad Pharma Inc | Kinase inhibitor phosphorus derivatives |
US20130225528A1 (en) | 2008-05-21 | 2013-08-29 | Ariad Pharmaceuticals, Inc. | Phosphorus Derivatives as Kinase Inhibitors |
CN102089278A (zh) | 2008-06-11 | 2011-06-08 | Irm责任有限公司 | 用于治疗疟疾的化合物和组合物 |
AU2009271414A1 (en) | 2008-06-20 | 2010-01-21 | Metabolex, Inc. | Aryl GPR119 agonists and uses thereof |
EP3549934A1 (en) | 2008-06-27 | 2019-10-09 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
NZ591226A (en) | 2008-09-02 | 2012-11-30 | Boehringer Ingelheim Int | Benzoic acid amides, production thereof, and use thereof as medicaments |
US20110230478A1 (en) | 2008-09-03 | 2011-09-22 | Bayer ScienceCrop AG | 4-Alkyl-substituted diaminopyrimidines |
RU2014150660A (ru) | 2008-09-05 | 2015-07-20 | Селджен Авиломикс Рисерч, Инк. | Алгоритм разработки необратимо действующих ингибиторов |
WO2010044885A2 (en) | 2008-10-17 | 2010-04-22 | Whitehead Institute For Biomedical Research | Soluble mtor complexes and modulators thereof |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
CN101723936B (zh) | 2008-10-27 | 2014-01-15 | 上海睿星基因技术有限公司 | 激酶抑制剂及其在药学中的用途 |
US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
WO2010056311A1 (en) | 2008-11-12 | 2010-05-20 | Ariad Pharmaceuticals, Inc. | Pyrazinopyrazines and derivatives as kinase inhibitors |
JP2012511575A (ja) | 2008-12-12 | 2012-05-24 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのアザインドール誘導体 |
WO2010072155A1 (zh) | 2008-12-26 | 2010-07-01 | 复旦大学 | 一种嘧啶类衍生物及其制备方法和用途 |
WO2010080712A2 (en) | 2009-01-06 | 2010-07-15 | Dana Farber Cancer Institute | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
EP2396342B1 (en) | 2009-02-12 | 2014-09-17 | Cell Signaling Technology, Inc. | Mutant ros expression in human liver cancer |
WO2010098866A1 (en) | 2009-02-27 | 2010-09-02 | Supergen, Inc. | Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors |
US20110071158A1 (en) | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
WO2010111406A2 (en) | 2009-03-24 | 2010-09-30 | Myriad Pharmaceuticals, Inc. | Compounds and therapeutic uses thereof |
ES2423804T3 (es) | 2009-04-03 | 2013-09-24 | Cellzome Gmbh | Métodos para la identificación de moléculas que interaccionan con cinasas y para la purificación de proteínas de cinasa |
KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Egfr 억제제 및 질환 치료방법 |
US8410126B2 (en) | 2009-05-29 | 2013-04-02 | Boehringer Ingelheim International Gmbh | Pyrimidine inhibitors of PKTK2 |
US20120142667A1 (en) | 2009-06-10 | 2012-06-07 | Nigel Ramsden | Pyrimidine derivatives as zap-70 inhibitors |
EP2443095A1 (en) | 2009-06-18 | 2012-04-25 | Cellzome Limited | Sulfonamides and sulfamides as zap-70 inhibitors |
KR101906146B1 (ko) | 2009-08-17 | 2018-10-10 | 메모리얼 슬로안-케터링 캔서 센터 | 열 충격 단백질 결합 화합물, 조성물, 및 이의 제조 방법 및 사용 방법 |
SG179085A1 (en) | 2009-09-09 | 2012-04-27 | Avila Therapeutics Inc | Pi3 kinase inhibitors and uses thereof |
NZ620174A (en) | 2009-09-16 | 2016-08-26 | Celgene Avilomics Res Inc | Protein kinase conjugates and inhibitors |
ES2567280T3 (es) | 2009-09-25 | 2016-04-21 | Vertex Pharmaceuticals Incorporated | Métodos para preparar derivados de pirimidina útiles como inhibidores de proteína quinasa |
WO2011053518A1 (en) | 2009-10-26 | 2011-05-05 | Signal Pharmaceuticals, Llc | Methods of synthesis and purification of heteroaryl compounds |
WO2011079231A1 (en) | 2009-12-23 | 2011-06-30 | Gatekeeper Pharmaceutical, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
WO2011082285A1 (en) | 2009-12-30 | 2011-07-07 | Avila Therapeutics, Inc. | Ligand-directed covalent modification of protein |
CA2789711C (en) | 2010-02-17 | 2014-08-05 | Amgen Inc. | Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain |
US8383793B2 (en) | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
US20130137709A1 (en) | 2010-05-05 | 2013-05-30 | Nathanael S. Gray | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith |
AU2011253003B2 (en) | 2010-05-13 | 2014-05-01 | Amgen Inc. | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors |
DK2975042T3 (en) | 2010-06-23 | 2019-01-21 | Hanmi Science Co Ltd | Novel fused pyrimidine derivatives to inhibit tyrosine kinase activity |
BR112013003388A2 (pt) | 2010-08-10 | 2016-07-12 | Celgene Avilomics Res Inc | sal de besilato de um inibidor de btk |
WO2012022045A1 (en) | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
WO2012051587A1 (en) | 2010-10-14 | 2012-04-19 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in egfr-driven cancers |
JP5957460B2 (ja) | 2010-11-01 | 2016-07-27 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | 複素環式化合物またはその使用 |
WO2012061303A1 (en) | 2010-11-01 | 2012-05-10 | Avila Therapeutics, Inc. | Heteroaryl compounds and uses thereof |
US8796255B2 (en) | 2010-11-10 | 2014-08-05 | Celgene Avilomics Research, Inc | Mutant-selective EGFR inhibitors and uses thereof |
EA201391626A1 (ru) | 2011-05-04 | 2014-03-31 | Ариад Фармасьютикалз, Инк. | Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака |
JP5427321B2 (ja) | 2011-07-27 | 2014-02-26 | アストラゼネカ アクチボラグ | 2−(2,4,5−置換−アニリノ)ピリミジン化合物 |
MD20140023A2 (ro) | 2011-09-22 | 2014-06-30 | Pfizer Inc. | Derivaţi de pirolpirimidină şi purină |
US20150166591A1 (en) | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
-
2009
- 2009-05-21 HU HUE09751617A patent/HUE035029T2/en unknown
- 2009-05-21 KR KR1020167030856A patent/KR101860057B1/ko active Protection Beyond IP Right Term
- 2009-05-21 KR KR1020107028717A patent/KR101781605B1/ko active Protection Beyond IP Right Term
- 2009-05-21 AU AU2009248923A patent/AU2009248923B2/en active Active
- 2009-05-21 KR KR1020187003282A patent/KR101956261B1/ko active IP Right Grant
- 2009-05-21 MX MX2015016748A patent/MX353308B/es unknown
- 2009-05-21 WO PCT/US2009/044918 patent/WO2009143389A1/en active Application Filing
- 2009-05-21 PL PL09751617T patent/PL2300013T3/pl unknown
- 2009-05-21 ES ES09751617.3T patent/ES2645689T3/es active Active
- 2009-05-21 JP JP2011510716A patent/JP2011523646A/ja not_active Withdrawn
- 2009-05-21 DK DK09751617.3T patent/DK2300013T3/en active
- 2009-05-21 EA EA201071339A patent/EA029131B1/ru active Protection Beyond IP Right Term
- 2009-05-21 PT PT97516173T patent/PT2300013T/pt unknown
- 2009-05-21 NO NO09751617A patent/NO2300013T3/no unknown
- 2009-05-21 EP EP09751617.3A patent/EP2300013B1/en active Active
- 2009-05-21 EP EP17162419.0A patent/EP3210609A1/en active Pending
- 2009-05-21 BR BRPI0908637A patent/BRPI0908637B8/pt active IP Right Grant
- 2009-05-21 CA CA2723961A patent/CA2723961C/en active Active
- 2009-05-21 US US12/736,910 patent/US9012462B2/en active Active
- 2009-05-21 LT LTEP09751617.3T patent/LT2300013T/lt unknown
- 2009-05-21 CN CN200980128664.3A patent/CN102105150B/zh active Active
- 2009-05-21 MX MX2010012703A patent/MX2010012703A/es unknown
- 2009-05-21 SI SI200931753T patent/SI2300013T1/en unknown
-
2010
- 2010-10-14 IL IL208716A patent/IL208716B/en active Protection Beyond IP Right Term
-
2011
- 2011-11-28 HK HK11112863.6A patent/HK1158497A1/xx unknown
-
2015
- 2015-04-20 US US14/690,916 patent/US20150225436A1/en not_active Abandoned
- 2015-04-22 JP JP2015087857A patent/JP6190415B2/ja active Active
-
2017
- 2017-04-17 US US15/489,593 patent/US20170218000A1/en not_active Abandoned
- 2017-05-02 JP JP2017091616A patent/JP6271064B2/ja active Active
- 2017-10-11 HR HRP20171534TT patent/HRP20171534T8/hr unknown
- 2017-10-26 CY CY20171101120T patent/CY1119534T1/el unknown
- 2017-12-26 JP JP2017248633A patent/JP6483233B2/ja active Active
-
2018
- 2018-01-22 IL IL257083A patent/IL257083B/en active IP Right Grant
-
2019
- 2019-02-13 JP JP2019023097A patent/JP6690032B2/ja active Active
- 2019-04-19 US US16/389,623 patent/US20200048288A1/en not_active Abandoned
- 2019-05-17 FR FR19C1033C patent/FR19C1033I2/fr active Active
- 2019-05-17 LU LU00120C patent/LUC00120I2/en unknown
- 2019-05-17 NL NL300990C patent/NL300990I2/nl unknown
- 2019-05-17 LT LTPA2019510C patent/LTC2300013I2/lt unknown
- 2019-05-20 NO NO2019024C patent/NO2019024I1/no unknown
- 2019-05-20 CY CY2019027C patent/CY2019027I2/el unknown
- 2019-05-20 HU HUS1900029C patent/HUS1900029I1/hu unknown
- 2019-11-01 US US16/672,205 patent/US20200317705A1/en not_active Abandoned
-
2020
- 2020-04-08 JP JP2020069505A patent/JP2020125308A/ja active Pending
-
2022
- 2022-05-13 JP JP2022079291A patent/JP2022116057A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR19C1033I2 (fr) | Derives phosphores servant d'inhibiteurs de kinase | |
LTC3106463I2 (lt) | Pakeistieji pirazolo[1,5-a]pirimidino junginiai kaip trk kinazės slopikliai | |
FR20C1064I2 (fr) | Derives d'indazole substitues actifs comme inhibiteurs de kinases | |
CU23886B1 (es) | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b | |
BRPI0918846A2 (pt) | inibidores de cinase heterocíclica | |
SMT201400123B (it) | Imidazo[1,2B]piridazine sostituite come inibitori di trk-chinasi | |
BRPI0907563A2 (pt) | Derivados de 4,5-di-hidro-xazol-2-il amina | |
BRPI0922880A2 (pt) | compostos inibidores de quinase | |
BRPI0920135A2 (pt) | imidazopiridazinacarbonitrilos úteis como inibidores de quinase | |
BRPI0811434A2 (pt) | imidazopiridazinas como inibidores de pi3k lipídeo cinase. | |
BRPI0910668A2 (pt) | inibidores de proteína quinases | |
SMAP200800022A (it) | Benzimidazoli sostituiti come inibitori delle chinasi | |
ATE506358T1 (de) | 2-benzylpyridazinonderivate als met-kinasehemmer | |
BRPI0716477A2 (pt) | Derivados heteroarila como inibidores de quinase protéica | |
BR112012004448A2 (pt) | "compostos e composições como inibidores de proteína cinase" | |
BRPI0912475A8 (pt) | compostos como inibidores de quinase | |
CR10879A (es) | Cyclized derivatives as eg-5 inhibitors | |
BRPI0906357A2 (pt) | Derivados de oxazepinopirimidona arilamida substituídos | |
BRPI0811517A2 (pt) | Compostos e composições como inibidores de c-kit e pdgfr cinase. | |
BRPI0921509A2 (pt) | inibidor triazolotiadiazol de proteína quinase c-met | |
BRPI0716198A2 (pt) | Pirrolo-isoquinolinas como inibidores de cinase | |
DK2170891T3 (da) | Pyrazolopyrimidinon-kinasehæmmere | |
FR2915747B1 (fr) | Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatase cdc25 | |
BRPI0719883A2 (pt) | Inibidores de quinase | |
FR2934997B1 (fr) | Derives cyclopropyl-et cyclobutyl-dioxazaborocanes ou dioxazaborecanes |